Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AMIT R PALIWAL

Allopathic & Osteopathic Physicians Family Medicine

NPI
1790881159
CMS profile
81770
Location
POMONA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$223.29

13 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $223.29 13

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AMIT R PALIWAL

NPI 1790881159 · CMS profile ID 81770

Allopathic & Osteopathic Physicians / Family Medicine

POMONA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1790881159?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AMIT R PALIWAL, NPI 1790881159, CMS profile ID 81770. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790881159?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). AMIT R PALIWAL, NPI 1790881159, CMS profile ID 81770. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790881159?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
AMIT R PALIWAL, NPI 1790881159, CMS profile ID 81770, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1790881159?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

13 matching records · $223.29 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 13 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–13 of 13.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $13.8512/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743800323 CMS
Janssen Pharmaceuticals, Inc $21.5511/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787403751 CMS
Novartis Pharmaceuticals Corporation $16.8110/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726058593 CMS
Venclose Inc. $6.0609/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750113823 CMS
Venclose Inc. $18.7309/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750113825 CMS
PFIZER INC. $13.2508/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743758969 CMS
PFIZER INC. $15.4007/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743748613 CMS
Boston Scientific Corporation $17.6406/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725481299 CMS
Merck Sharp & Dohme Corporation $22.4502/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747732445 CMS
Amgen Inc. $23.9602/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740897745 CMS
Janssen Pharmaceuticals, Inc $20.2502/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718978363 CMS
Janssen Pharmaceuticals, Inc $18.8301/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718978371 CMS
Mannkind Corporation $14.5101/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752677003 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,553.93 9
PY2020 $223.29 13
PY2021 $428.97 25
PY2022 $224.04 9
PY2023 $595.36 30
PY2024 $2,420.66 49
PY2025 $474.30 17

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $336,771.75 76
PY2024 Principal investigator $1,437,539.26 120
PY2023 Principal investigator $2,154,474.59 360
PY2022 Principal investigator $1,373,629.94 603
PY2021 Principal investigator $148,509.98 11
PY2020 Principal investigator $14,597.00 9
PY2019 Principal investigator $78,504.30 23

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

120 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $907.26 12/18/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147184169
Principal investigator 1 ModernaTX, Inc. $13,804.97 12/18/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147184171
Principal investigator 1 Janssen Research & Development, LLC $20,569.00 12/17/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952323
Principal investigator 1 ModernaTX, Inc. $121,604.59 12/06/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147184163
Principal investigator 1 ModernaTX, Inc. $25,337.86 12/06/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147184165
Principal investigator 1 ModernaTX, Inc. $21,474.12 12/06/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147184167
Principal investigator 1 ModernaTX, Inc. $48,348.90 12/02/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147184173
Principal investigator 1 ModernaTX, Inc. $6,780.91 11/20/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147184161
Principal investigator 1 Janssen Research & Development, LLC $17,736.00 11/18/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952297
Principal investigator 1 ModernaTX, Inc. $1,575.00 11/15/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147184155
Principal investigator 1 ModernaTX, Inc. $2,000.00 11/15/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147184157
Principal investigator 1 ModernaTX, Inc. $1,160.00 11/15/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147184159
Principal investigator 1 ModernaTX, Inc. $31,673.04 10/18/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147184143
Principal investigator 1 ModernaTX, Inc. $2,716.74 10/18/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147184145
Principal investigator 1 Organon LLC $3,650.00 10/18/2024 Non-covered Recipient Entity
Empire Clinical Research, LLC
OG-8175A-023 No dispute reported 06/30/2026 1125523633
Principal investigator 1 ModernaTX, Inc. $8,796.12 10/16/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147184183
Principal investigator 1 Janssen Research & Development, LLC $6,611.00 10/15/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952347
Principal investigator 1 PFIZER INC. $103,212.30 09/25/2024 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1130909773
Principal investigator 1 ModernaTX, Inc. $8,454.91 09/20/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147184139
Principal investigator 1 ModernaTX, Inc. $7,885.22 09/18/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147184141
Principal investigator 1 Janssen Research & Development, LLC $18,865.00 09/12/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952305
Principal investigator 1 ModernaTX, Inc. $13,482.86 08/28/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147184131
Principal investigator 1 ModernaTX, Inc. $106,436.16 08/23/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147184127
Principal investigator 1 ModernaTX, Inc. $14,890.71 08/21/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147184129
Principal investigator 1 Janssen Research & Development, LLC $756.00 08/19/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952247
Principal investigator 1 Janssen Research & Development, LLC $8,926.00 08/15/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952289
Principal investigator 1 Janssen Research & Development, LLC $30,744.00 08/12/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952327
Principal investigator 1 PFIZER INC. $3,500.00 08/03/2024 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1130905555
Principal investigator 1 Janssen Research & Development, LLC $950.00 08/01/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952299
Principal investigator 1 Janssen Research & Development, LLC $1,404.00 08/01/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952319
Principal investigator 1 PFIZER INC. $2,980.80 08/01/2024 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1130905551
Principal investigator 1 ModernaTX, Inc. $2,169.83 07/26/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147184123
Principal investigator 1 Janssen Research & Development, LLC $3,693.00 07/25/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952241
Principal investigator 1 Galderma Laboratories, L.P. $11,147.40 07/18/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab No dispute reported 06/30/2026 1156049029
Principal investigator 1 ModernaTX, Inc. $11,859.62 07/17/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147184125
Principal investigator 1 ModernaTX, Inc. $1,472.50 07/03/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147184119
Principal investigator 1 ModernaTX, Inc. $25,862.81 07/03/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147184121
Principal investigator 1 Janssen Research & Development, LLC $1,512.00 07/01/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952277
Principal investigator 1 Janssen Research & Development, LLC $2,772.00 06/28/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952257
Principal investigator 1 Janssen Research & Development, LLC $94,278.00 06/28/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952303
Principal investigator 1 Janssen Research & Development, LLC $468.00 06/25/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952239
Principal investigator 1 Janssen Research & Development, LLC $234.00 06/25/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952243
Principal investigator 1 Janssen Research & Development, LLC $10,080.00 06/25/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952245
Principal investigator 1 Janssen Research & Development, LLC $312.00 06/25/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952263
Principal investigator 1 Janssen Research & Development, LLC $1,410.00 06/25/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952265
Principal investigator 1 Janssen Research & Development, LLC $100.00 06/25/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952269
Principal investigator 1 Janssen Research & Development, LLC $1,308.00 06/25/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952271
Principal investigator 1 Janssen Research & Development, LLC $156.00 06/25/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952291
Principal investigator 1 Janssen Research & Development, LLC $12,605.00 06/25/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952301
Principal investigator 1 Janssen Research & Development, LLC $754.00 06/25/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952309
Principal investigator 1 Janssen Research & Development, LLC $1,008.00 06/25/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952311
Principal investigator 1 Janssen Research & Development, LLC $1,008.00 06/25/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952313
Principal investigator 1 Janssen Research & Development, LLC $856.00 06/25/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952331
Principal investigator 1 Janssen Research & Development, LLC $2,318.00 06/25/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952333
Principal investigator 1 Janssen Research & Development, LLC $780.00 06/25/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952335
Principal investigator 1 Janssen Research & Development, LLC $1,008.00 06/25/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952337
Principal investigator 1 Janssen Research & Development, LLC $78.00 06/25/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952375
Principal investigator 1 Janssen Research & Development, LLC $156.00 06/25/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952379
Principal investigator 1 Janssen Research & Development, LLC $550.00 06/25/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952383
Principal investigator 1 Janssen Research & Development, LLC $2,116.00 06/24/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952283
Principal investigator 1 Janssen Research & Development, LLC $156.00 06/24/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952317
Principal investigator 1 ModernaTX, Inc. $15,372.18 06/21/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147184117
Principal investigator 1 Janssen Research & Development, LLC $13,046.00 06/18/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952359
Principal investigator 1 PFIZER INC. $3,500.00 06/05/2024 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1130906050
Principal investigator 1 Mylan Inc. $449.54 05/27/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY No dispute reported 06/30/2026 1134126625
Principal investigator 1 ModernaTX, Inc. $730.79 05/24/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147184115
Principal investigator 1 Janssen Research & Development, LLC $12,605.00 05/22/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952355
Principal investigator 1 ModernaTX, Inc. $27,260.28 05/22/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147184113
Principal investigator 1 Janssen Research & Development, LLC $1,008.00 05/14/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952267
Principal investigator 1 ModernaTX, Inc. $8,165.34 05/08/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147184111
Principal investigator 1 PFIZER INC. $2,043.75 05/08/2024 Non-covered Recipient Entity
Pasadena Clinical Trials LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130910712
Principal investigator 1 Janssen Research & Development, LLC $1,308.00 04/30/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952249
Principal investigator 1 Janssen Research & Development, LLC $78.00 04/30/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952259
Principal investigator 1 Janssen Research & Development, LLC $312.00 04/30/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952273
Principal investigator 1 Janssen Research & Development, LLC $2,318.00 04/30/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952285
Principal investigator 1 Janssen Research & Development, LLC $234.00 04/30/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952325
Principal investigator 1 Janssen Research & Development, LLC $754.00 04/30/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952339
Principal investigator 1 Janssen Research & Development, LLC $468.00 04/30/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952341
Principal investigator 1 Janssen Research & Development, LLC $1,410.00 04/30/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952381
Principal investigator 1 PFIZER INC. $2,980.80 04/25/2024 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1130907329
Principal investigator 1 Janssen Research & Development, LLC $13,046.00 04/23/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952307
Principal investigator 1 ModernaTX, Inc. $34,041.56 04/10/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147184109
Principal investigator 1 Janssen Research & Development, LLC $21,491.00 04/09/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952261
Principal investigator 1 ModernaTX, Inc. $3,297.34 04/01/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147184107
Principal investigator 1 ModernaTX, Inc. $3,683.00 03/27/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147184099
Principal investigator 1 Mylan Inc. $1,042.72 03/27/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY No dispute reported 06/30/2026 1134126623
Principal investigator 1 ModernaTX, Inc. $6,486.75 03/22/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147184101
Principal investigator 1 ModernaTX, Inc. $4,000.00 03/22/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147184103
Principal investigator 1 ModernaTX, Inc. $32,175.53 03/21/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147184181
Principal investigator 1 ModernaTX, Inc. $25,838.84 03/20/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147184097
Principal investigator 1 ModernaTX, Inc. $154,049.34 03/20/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147184179
Principal investigator 1 ModernaTX, Inc. $500.00 03/13/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147184105
Principal investigator 1 PFIZER INC. $322.92 03/08/2024 Non-covered Recipient Entity
Pasadena Clinical Trials LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130909056
Principal investigator 1 Janssen Research & Development, LLC $16,976.00 02/28/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952279
Principal investigator 1 Janssen Research & Development, LLC $390.00 02/28/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952287
Principal investigator 1 Janssen Research & Development, LLC $754.00 02/28/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952345
Principal investigator 1 Janssen Research & Development, LLC $502.00 02/27/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952255
Principal investigator 1 Janssen Research & Development, LLC $390.00 02/27/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952365
Principal investigator 1 PFIZER INC. $7,476.16 02/27/2024 Non-covered Recipient Entity
Empire Clinical Research LLC
AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS No dispute reported 06/30/2026 1130905505
Principal investigator 1 ModernaTX, Inc. $13,058.82 02/21/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147184091
Principal investigator 1 Janssen Research & Development, LLC $2,266.00 02/16/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952321
Principal investigator 1 Janssen Research & Development, LLC $390.00 02/16/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952377
Principal investigator 1 ModernaTX, Inc. $29,781.42 02/16/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147184093
Principal investigator 1 PFIZER INC. $10,820.00 02/14/2024 Non-covered Recipient Entity
Pasadena Clinical Trials LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130905018
Principal investigator 1 PFIZER INC. $10,900.00 02/12/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS No dispute reported 06/30/2026 1130906536
Principal investigator 1 PFIZER INC. $1,458.60 02/09/2024 Non-covered Recipient Entity
Empire Clinical Research LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1130909005
Principal investigator 1 PFIZER INC. $10,820.00 02/08/2024 Non-covered Recipient Entity
Empire Clinical Research LLC
AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS No dispute reported 06/30/2026 1130907294
Principal investigator 1 ModernaTX, Inc. $450.00 02/07/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147184089
Principal investigator 1 ModernaTX, Inc. $325.00 02/07/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147184177
Principal investigator 1 ModernaTX, Inc. $2,500.00 02/02/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147184095
Principal investigator 1 ModernaTX, Inc. $821.34 01/29/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147184175
Principal investigator 1 Janssen Research & Development, LLC $4,178.00 01/24/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952349
Principal investigator 1 Janssen Research & Development, LLC $936.00 01/24/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952361
Principal investigator 1 ModernaTX, Inc. $30,265.65 01/24/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147184087
Principal investigator 1 Janssen Research & Development, LLC $1,206.00 01/23/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952275
Principal investigator 1 Janssen Research & Development, LLC $780.00 01/23/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952369
Principal investigator 1 ModernaTX, Inc. $29,380.72 01/17/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147184085
Principal investigator 1 Janssen Research & Development, LLC $7,371.00 01/16/2024 Non-covered Recipient Entity
Empire Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078952251
Principal investigator 1 Mylan Inc. $5,488.13 01/11/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY No dispute reported 06/30/2026 1134126621
Principal investigator 1 Mylan Inc. $4,374.11 01/10/2024 Non-covered Recipient Entity
EMPIRE CLINICAL RESEARCH LLC
MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY No dispute reported 06/30/2026 1134126619